Jul 2, 2026 06:42AM
Jun 22, 2026 08:01AM
Jun 22, 2026 08:00AM
May 30, 2026 10:00AM
May 30, 2026 10:00AM
May 21, 2026 05:00PM
May 19, 2026 08:00AM Exelixis partners with Merck for colorectal cancer trial
May 19, 2026 08:00AM
May 5, 2026 04:05PM
Feb 10, 2026 04:05PM
Feb 4, 2026 07:08AM
Feb 2, 2026 08:03AM
Feb 2, 2026 08:00AM
Jan 12, 2026 04:05AM Exelixis reports $2.123 billion preliminary 2025 revenues, guides higher for 2026
Jan 11, 2026 04:00PM
Dec 12, 2025 10:31AM
Nov 4, 2025 04:05PM
Oct 21, 2025 07:00AM
Oct 18, 2025 03:00AM
Oct 18, 2025 03:00AM
Jul 28, 2025 04:05PM Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
Jul 24, 2025 05:04PM
Jul 24, 2025 05:04PM
Jul 24, 2025 04:31AM
Jun 20, 2025 06:54AM
May 13, 2025 04:07PM
Apr 12, 2025 04:00AM
Mar 27, 2025 06:37AM H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL)
Mar 26, 2025 01:08PM
Mar 26, 2025 01:07PM
Mar 26, 2025 10:56AM
Mar 26, 2025 09:15AM
Mar 26, 2025 09:15AM
Mar 25, 2025 05:15PM
Feb 15, 2025 11:10AM Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at
Feb 11, 2025 04:05PM
Jan 24, 2025 02:31PM
Jan 24, 2025 02:30PM
Jan 15, 2025 05:11PM
Jan 13, 2025 12:50PM
Jan 12, 2025 04:00PM
Jan 9, 2025 09:00AM Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
Dec 19, 2024 11:16AM
Dec 17, 2024 08:00AM
Nov 27, 2024 07:08AM
Nov 26, 2024 04:05PM
Oct 29, 2024 04:05PM
Oct 15, 2024 01:57PM
Oct 15, 2024 01:57PM Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
Oct 14, 2024 08:02AM

325,890 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All